Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

• Status: RECRUITING
• Trial end date: 2029-07-01

Summary

This Phase 2, open-label, randomized study in non-small-cell lung cancer (NSCLC) is designed to evaluate the efficacy and safety of an intravenously delivered oncolytic vaccinia virus, Olvi-Vec, followed by platinum-doublet chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor (ICI) vs. docetaxel for patients with advanced or metastatic NSCLC who have shown first disease progression (i.e., progressive disease not yet confirmed by further scan after initial scan showing progression) while on front-line treatment or maintenance ICI therapy after front-line treatment with platinum-doublet chemotherapy + ICI as standard of care.

• Phase: PHASE2

Details

• Lead Sponsor: Genelux Corporation
• Collaborator: Newsoara Biopharma Co., Ltd.
• Treatments: 130-nm albumin-bound paclitaxel; atezolizumab; cemiplimab; Cisplatin; Docetaxel; durvalumab; Nivolumab; Pemetrexed